Overview of the drug development for ALK inhibitors for NSCLC
It has been observed that NSCLC is one of the major type of lung cancer. It develops when lung cells start to grow uncontrollably. It can further be categorized into subtypes based on types of lung cells involved including squamous cell carcinoma, adenocarcinoma, and large cell carcinoma, but they all are clustered together as NSCLC due to similar treatment and prognosis approach. The ALK fusion gene, which is a component in the lung cells, gets abnormally activated in NSCLC, which can further result in an uncontrolled cell growth. The ALK gene is fused to the EML4 gene in anaplastic lymphoma kinase-positive lung cancer. ALK+ lung cancer is not always associated with smoking and can be developed in non-smokers also. According to the NIH, lung cancer is the most common type of cancer responsible for deaths in both men and women in the US. NSCLC accounts for more than 85% of all lung cancers. Furthermore, according to CDC, lung cancer is the leading cause of cancer mortality and the second most diagnosed cancer in both men and women in the US. Consequently, the rising incidences of NSCLC is further expected to promote the drug development for ALK inhibitors for NSCLC.
According to this pipeline analysis report, most of the drug development molecules in the pipeline are being developed for NSCLC. Our market research analysts have also identified that most of these molecules are in the pre-clinical development stage and a considerable number of molecules have been discontinued from development.
Companies covered
This pipeline analysis report provides a detailed analysis of the companies that are involved in the development of gene therapy molecules for the treatment of NSCLC. In addition to providing information on the various stages of molecules developed by companies for different indications, this pipeline analysis report also provides information about the gene therapy molecules discontinued by companies.
Some of the companies covered in this pipeline analysis report are –
- Igyta
- Pfizer
- Xcovery
Therapeutic assessment of the drug development pipeline for ALK inhibitors for NSCLC by route of administration
- Oral
The oral route of administration (ROA) involves the application of the drug directly through the mouth cavity, which will have a more direct effect on the target cells.
Therapeutic assessment of the drug development pipeline for ALK inhibitors for NSCLC for AMD by therapy
- Monotherapy
- Combination therapy
According to this pipeline analysis report, many of the molecules that are currently in the drug development for ALK inhibitors for NSCLC are being developed as monotherapy drugs and most of these molecules are in the pre-clinical stage of development.
Key questions answered in the report include
- What are the drug development molecules in the various development stages for ALK inhibitors for NSCLC?
- What are the companies that are currently involved in the drug development for ALK inhibitors for NSCLC?
- Insight into discontinued/inactive molecules with appropriate reasoning?
- What are the major regulatory authorities approving drugs in various regions?
- Detailed profiling of each active molecule
Technavio also offers customization on reports based on specific client requirement.